According to IMARC Group’s latest report, titled “Europe Medical Cannabis Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027,” the Europe medical cannabis market is currently witnessing moderate growth. Looking forward, the Europe medical cannabis market is expected to exhibit a CAGR of XX% during 2022-2027.
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Medical cannabis, or medicinal marijuana, refers to a psychotropic drug sourced from cannabis indica, sativa and hybrid plants. It majorly contains three active compounds, namely, tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN). These drugs are used to treat various chronic and stress-related diseases, such as insomnia, inflammation, depression, nausea, anorexia, epilepsy, and anxiety. Medical cannabis can be manufactured in the form of capsules, oils, topical solutions, vapor, smoke and eatables.
Request Free Sample Report: https://www.imarcgroup.com/europe-medical-cannabis-market/requestsample
The increasing prevalence of chronic diseases, especially amongst the geriatric population, is primarily driving the Europe medical cannabis market growth. In line with this, cannabis is safer and has fewer severe side effects than other treatment options, which is acting as a growth-inducing factor. Additionally, the widespread adoption of medical cannabis for effective pain management is further contributing to the market growth. Moreover, legalization and commercialization of cannabis-based medications through healthcare centers and authorized dispensaries is creating a positive outlook for the market in the region.
Ask Analyst and Browse Full Report with TOC & List of Figure: https://www.imarcgroup.com/europe-medical-cannabis-market
The competitive landscape of the industry has also been examined along with the profiles of the key players.
The report has segmented the market on the basis of species, derivative, application, end use, route of administration and country.
Breakup by Species:
Breakup by Derivative:
- Cannabidiol (CBD)
- Tetrahydrocannabinol (THC)
Breakup by Application:
Breakup by End Use:
- Pharmaceutical Industry
- Research and Development Centres
Breakup by Route of Administration:
- Oral Solutions and Capsules
Breakup by Country:
- United Kingdom
Key highlights of the report:
- Market Performance (2016-2021)
- Market Outlook (2022- 2027)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: [email protected]
Tel No:(D) +91 120 433 0800 Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
Follow us on Twitter: https://twitter.com/ImarcServices